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Abstract. We developed an MDR tumor model that is 
modulated by tumor-associated fibroblasts. Studies on prolif-
eration of tumor cell lines including paclitaxel-sensitive and 
resistant cell lines were performed. The expressions of P-gp 
and α-smooth muscle actin (α-SMA) antigen were evalu-
ated by immunohistochemistry and western blot analysis. 
Quantitative P-gp analyses of different cell lines were 
accomplished by nanoUPLC-MS/MS. Tumor cell colony 
formation assay and established xenograft model was used 
to investigate the relationship between P-gp expression, 
fibroblast levels and tumorigenesis. The mouse xenograft 
model was developed after co-inoculation with MDR tumor 
cells and NIH/3T3 fibroblast cells. There was no correlation 
between tumorigenesis in vivo and the growth rate of cells 
in vitro. The proliferation among different cell lines had no 
significant differences, but the P-gp expression and tumor 
growth in the xenograft model were fairly different. P-gp 
determination and α-SMA immunofluorescence staining 
clarified the relationship between P-gp expression, fibroblast 
levels and tumorigenesis. It was more difficult for tumor 
cells with higher P-gp levels to recruit fibroblasts in vivo, 
resulting in lower tumorigenesis due to the lack of structural 
and chemical support during tumor progression. In the estab-
lished paclitaxel-resistant mouse xenograft model, no obvious 
antitumor effect was observed after Taxol treatment, but a 
significant decrease in tumor size for the group treated with 
gemcitabine sensitive to the model. The results show that the 
added fibroblasts do not disturb the applicability of the model 
in MDR. Therefore, this mouse xenograft MDR model could 
serve as an effective tool for MDR research.
Introduction
A major obstacle to successful tumor chemotherapy is multi-
drug resistance (MDR), which has been widely investigated 
in recent decades (1). Numerous studies have been conducted 
into MDR mechanisms and strategies for overcoming MDR. 
Unfortunately, most patients still die from their disseminated 
cancer due to resistance to available anticancer drugs (2). 
Therefore, the development of an MDR model to screen novel 
therapy regimens for translation from the laboratory to the 
clinic is desperately needed.
An important tool in MDR research, the tumor models 
include three main types: the planar cell model, the three-
dimensional tumor model in vitro and the animal xenograft 
model. The in vitro monolayer cell model is easy to establish 
and is thus widely used in the early phase of tumor research. 
Its value, however, is limited due to its lack of relevance to 
clinical samples (3). Moreover, apart from the MDR tumor cell 
itself, the tumor microenvironment also plays an important, 
even dominant, role in MDR (4). The interaction between cells 
and extracellular matrices is extremely complex (5). To better 
mimic tumors in vivo, the three-dimensional matrix model 
was developed, leading to more physiologically relevant condi-
tions for assessing drug responses and studying biological 
mechanisms. In vitro 2-D cell and 3-D matrix models play 
an important role in understanding complex tumor systems 
but both are hardly sufficient for evaluating the real effects 
of products on tumors in vivo (6). Therefore, a whole animal 
xenograft model needs to be developed.
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When developing tumor models an issue with which many 
groups are confronted is that it is difficult for certain types of 
MDR tumor cell lines to grow with appropriate rate in vivo 
after being inoculated subcutaneously, even though the cells 
may grow quickly in a planar culture dish. In our laboratory, we 
found an interesting scientific phenomenon that three resistant 
tumor cell lines of KB-8-5, H460/Tax-R and NCI/ADR-ReS 
with gradually increasing expression of P-gp have similar 
proliferation rate in vitro, but in the xenograft model the higher 
the P-gp was expressed, the harder the model was to be estab-
lish. Normally, the xenograft models of KB-8-5 and H460/
Tax-R carcinoma lines in nude mice can be established within 
5 and 12 days or so, while the tumor of NCI-ADR-ReS cell 
lines in the nude mouse model shows hardly any growth (data 
not shown). In addition, the resistant KB-8-5 tumor models 
take on satisfactory reproduction and stability. Some tumor 
cell lines with low tumorigenesis have been reported (7), but 
few studies focus on the tumorigenic ability of MDR cells that 
have high P-gp (also known as MDR1; multidrug resistance 
protein 1) expression. Thus, we undertook such a study and 
developed a fast growing whole animal MDR tumor model 
with high level of P-gp expression.
Aside from the biological characteristics of tumor cells 
themselves, the tumor microenvironment contributes greatly 
to tumor growth and drug resistance (8). Fibroblasts, the 
most numerous and most important cells found in the tumor 
microenvironment, could affect tumor cell morphology, 
adhesion, proliferation and signaling by both structural and 
chemical means (6,9). Tumor-associated fibroblast (TAF) 
cells have been found to play a critical role in regulating the 
growth of adjacent tumor cells and vein endothelial cells 
via different growth factors such as VegF, HgF and bFgF. 
TAF cells promote tumorigenesis, and tumor cells that fail to 
recruit fibroblasts develop slowly (9,10). Some groups have 
employed fibroblasts to accelerate the growth rate of tumors 
by co-inoculation with cancer cell lines MCF-Ras, human 
PC-3 and MDA-436 (7,11). Solid tumor growth depends 
greatly on the formation of the stroma. Without mesenchyme, 
a tumor <2 mm in length cannot continue to grow (12).
Previous studies in our laboratory had already found 
highly significant expression of TAF cells within the 
harvested KB-8-5 tumor through the immunofluorescence 
of α-smooth muscle actin (α-SMA) in the tumor parafin 
sections and paclitaxel (Taxol) had no effect on the inhibi-
tion of tumor growth (unpublished data). Consequently, we 
hypothesize the in vivo growth of resistant tumor cells with 
high P-gp expression in nude mice depends on the TAF 
cells to a certain extent. We investigated the correlations 
among tumorgenesis, tumor cell growth profile in vitro, P-gp 
expression levels and fibroblast distribution profiles in tumor 
sections, and then develop a new in vivo MDR tumor mouse 
model by co-inoculating with resistant tumor cells and 
NIH/3T3 fibroblasts, which may be useful for the screening 
of antineoplastic agents and mechanistic studies of factors 
regulating tumor growth and progression.
Materials and methods
Materials. Taxol injection was manufactured by Hospira, Inc. 
(Lake Forest, IL, USA). gemcitabine was purchased from 
Sigma-Aldrich (St. Louis, Mo, USA). Antibodies against P-gp, 
α-SMA and gAPDH, horseradish peroxidase-conjugated 
anti-mouse and anti-rabbit whole Igg for western blot and 
fluorescence-conjugated anti-mouse and anti-rabbit whole Igg 
for immunofluorescence assay, were obtained from Santa Cruz 
Biotechnology (San Diego, CA, USA). Matrigel™ Basement 
Membrane Matrix was purchased from BD Biosciences (San 
Jose, CA, USA).
Sensitive KB-3-1 cell line (human mouth epidermal 
carcinoma cells) and the P-gp-overexpressing NCI/ADR-ReS 
cell line (human ovarian carcinoma cells) were obtained 
from the National Cancer Institute (Bethesda, MD, USA). 
Resistant KB-8-5 cells were separated from KB-3-1 cells. 
H460/Tax-R cell line (non-small lung carcinoma cells) was 
obtained from Dr Bingliang Fang at the MD Anderson Cancer 
Center (Houston, Tx, USA). NIH/3T3 fibroblast cells (mouse 
embryonic fibroblast cell line) were originally obtained from 
the American Type Culture Collection (ATCC; Manassas, VA, 
USA). Cells were maintained in RPMI-1640 or Dulbecco's 
modified eagle's medium (DMeM) containing 10% fetal 
bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml strep-
tomycin (all from Invitrogen, Carlsbad, CA, USA). Cells were 
cultivated at 37˚C with 5% Co2 in a humidified incubator.
Nude mice were purchased from the National Cancer 
Institute. All experiments performed on animals were in 
accordance with and approved by the institutional Animal 
Care and Use Committee at the University of North Carolina 
at Chapel Hill.
Western blot analysis. For in vitro preparations adhered cells 
in culture dishes were washed with ice-cold PBS, scraped 
off the dish using a cold plastic cell scraper, and the suspen-
sion gently transferred to a pre-cooled eppendorf tube. For 
in vitro studies the tumor-bearing mice were sacrificed and 
the tumors were removed. Whole cell suspensions or tumor 
lysates were extracted with RIPA buffer (~10 mg of tumor 
was mixed with 100 µl RIPA buffer), and the concentra-
tion of protein was quantified using a Pierce BCA Protein 
Assay kit (Thermo Scientific Inc., Rockford, IL, USA). 
Approximately 50 µg of protein from each sample was sepa-
rated on a NugAge 12% SDS-polyacrylamine gel, and then 
transferred to a polyvinylidene difluoride (PVDF) membrane 
(Bio-Rad, Hercules, CA, USA). The membrane was blocked 
with 5% skimmed milk in PBS for 1 h. After incubation with 
primary antibody at 4˚C overnight, the PVDF membrane was 
washed with PBST (0.2% Tween-80 in PBS), and then incu-
bated with secondary antibody for 1 h at room temperature. 
Antibodies against P-gp, α-SMA and GAPDh were used at 
1:2,000 dilutions. A HRP-conjugated anti-mouse antibody 
at a dilution of 1:10,000 or an HRP-conjugated anti-rabbit 
Igg at a dilution of 1:2,000 served as the secondary anti-
bodies in the experiment. The specific protein bands were 
visualized using a chemiluminescence kit (Pierce, Rockford, 
IL, USA). Chemiluminiscent signals were detected with the 
high-performance chemiluminescence film (ge Healthcare 
Bio-Sciences, Pittsburgh, PA, USA).
Targeted quantitative proteomic analysis for P-gp determina-
tion. Samples were prepared by modification of previously 
published targeted quantitative methods of ours (13,14). 
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Briefly, cells (~10 million), to which 0.5 ml 50 mM ammonium 
bicarbonate had been added, were homogenized in a 2-ml 
glass homogenizer (Wheaton, Millville, NJ, USA). Following 
centrifugation at 16,000 x g for 10 min the supernatant was 
discarded and the pellet solubilized, with further homogeniza-
tion, in 0.5 ml of 1% sodium deoxycholate. The homogenate 
was centrifuged again at 16,000 x g for 10 min and the pellet 
discarded. Total protein concentration of the supernatant was 
measured using the Pierce BCA Protein Assay kit (Thermo 
Scientific Inc.).
Membrane samples (25 µg/replicate) were analyzed 
in duplicate. β-casein (0.5 µg, from bovine milk; Sigma-
Aldrich) was added as a general indicator of successful 
digestion. Samples were denatured with heat, reduced with 
dithiothreitol and carbamidomethylated with iodoacetamide. 
Trypsin solution (0.01 µg/µl) was added to give a cell protein 
to trypsin ratio of 20:1 and samples were digested at 37˚C for 
4 h (pH ~8; 50 mM ammonium bicarbonate buffer), shaking 
at 300 rpm. The reaction was stopped by addition of 10% 
trifluoroacetic acid, the amount added being 10% of the total 
reaction volume. Following centrifugation at 13,400 x g for 
5 min the supernatant was treated with solid phase extrac-
tion (C18 cartridges, Strata-x, 33u, polymeric, 10 mg/ml; 
Phenomenex, Torrance, CA, USA). The eluate was evaporated, 
reconstituted and analyzed by nanoUPLC-MS/MS as previ-
ously described (13,14).
Two of the proteotypic P-gp tryptic peptides targeted in the 
nano-uPLC-MS/MS analysis were i368iDNKPSiDSYSK380 
and i896ATeAIeNFR905. Two MRMs were acquired per 
peptide and peak areas were used to compare samples. The 
two MRM areas were averaged and then the areas for the 
duplicates were averaged. Results for peptides were compared 
between cell samples.
Cell proliferation assay. Four types of tumor cell lines, namely 
KB-3-1, KB-8-5, H460/Tax-R and NCI/ADR-ReS cells, were 
seeded in 6-well plates at a density of 40,000 cells/well and 
incubated at atmospheric pressure at 37˚C with 5 % Co2. 
over the following week, cells in each well were harvested 
and counted using a cell counting plate. The cell number was 
plotted against time.
Tumor cell colony formation assay. To perform the tumor 
cell colony formation assay, 1.2 and 0.7% agarose solutions 
were first prepared. The solutions were melted in a microwave 
oven and cooled to 40˚C in a water bath before use. An equal 
volume of 1.2% agarose was mixed with 2x RPMI-1640 
containing 20% FBS and antibiotics to give base agarose. 
one milliliter of this mixture was added to each well of 
a 6-well plate and allowed to solidify for 5 min. Following 
this, 1 ml of 0.7% agarose, mixed with 2x RPMI-1640 and 
2,500 cells, was plated gently onto the surface of the base 
agarose. 1x RPMI-1640 (0.5 ml) of medium was then added 
to each well and the plate was incubated at 37˚C for 15 days. 
Cells were washed 1-2 times/week with cell culture medium. 
At day 15, cell colonies were photographed after staining with 
0.5 ml of 0.005% crystal violet for 15 min.
Mouse xenograft model development and tumor growth. 
Female nude mice (6-8 weeks) were used in all studies. The 
mice were divided into 6 groups, each receiving the following 
cells via subcutaneous injection into their right or left flanks: 
i), KB-3-1 cells (5x106); ii), KB-8-5 cells (5x106); iii), H460/Tax-R 
cells (5x106); iv), NCI/ADR-ReS cells (5x106); v), H460/Tax-R 
(5x106) and NIH/3T3 cells (2.5x106); and vi), NCI/ADR-ReS 
(5x106) and NIH/3T3 cells (2.5x106). Cells of group v and vi 
were mixed with Matrigel™Basement Membrane Matrix at a 
ratio of 2:1 (w/w) before injection. Images of the mice were 
taken with a digital camera 16 days after tumor cell inoculation.
Sensitivity of the MDR tumor model to chemotherapy. 
Tumor sensitivity to chemotherapy was evaluated in the 
NCI/ADR-ReS and H460/Tax-R cell-bearing nude mouse 
models. once the tumor mass in the xenograft was established, 
mice were randomly divided into 3 groups (5 mice/group) and 
were injected, in the tail vein, with normal saline (the control 
group), Taxol or gemcitabine. Drug doses of 10 mg/kg PTx 
and 9 mg/kg gemcitabine were used for all treatments. Therapy 
was continued at days 3, 5, 7 and 9 (5 doses in total). Mice were 
sacrificed when the tumor reached 2 cm in length, and tumor 
volumes were calculated using the following equation: (length 
x width2)/2.
Immunofluorescence assay. Harvested tumors were fixed 
in 4.0% paraformaldehyde (PFA), paraffin-embedded, and 
sectioned at the UNC Lineberger Comprehensive Cancer 
Center Animal Histopathology Facility. For immunofluores-
cence of P-gp and α-SMA, slides were subjected to block by 
BSA after deparaffinization, dehydration and antigen retrieval. 
Slides were then incubated with primary antibodies (diluted 
by 1% BSA) at 4˚C overnight and with secondary antibodies 
at room temperature for 1 h. Nuclei were fluorescently stained 
with 4',6-diamidino-2-phenylindole (DAPI) Vectashield 
(Vector Laboratories, Inc., Burlingame, CA, USA). Finally, 
all slides were photographed at 20-fold magnification. The 
primary antibodies for P-gp and α-SMA were diluted 200-fold 
and the secondary antibodies 100-fold.
Results and Discussion
Tumorigenesis of various tumor cell lines in vivo. KB-3-1, 
KB-8-5, H460/Tax-R and NCI/ADR-ReS are the four 
frequently used cell lines in tumor research. However, their 
tumor growth characteristics in vivo vary greatly. As shown 
in Fig. 1, obvious differences in tumorigenesis were observed 
in nude mice received subcutaneous inoculation with one 
of the four types of cell line. The graph in Fig. 1 shows that 
KB-3-1 and KB-8-5 grew much faster than H460/Tax-R 
and NCi/ADR-RES in vivo. The tumor volume increment 
of KB-8-5 was about 5- and 56-fold compared with that of 
H460/Tax-R and NCI/ADR-ReS. It suggests that KB-3-1 and 
KB-8-5 are the most tumorigenic of the cells. only a ‘tumor 
dot’ was observed in the mouse that was injected with h460/
Tax-R cells and no tumor was observed in the NCI/ADR-ReS- 
bearing mouse.
Correlations among cell proliferation, colony formation, 
P-gp expression and tumorigenesis in vitro and in vivo. To 
explore the reasons why tumorigenesis differs among tumor 
cell types, we firstly compared the growth rate and colony 
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formation ability of the cell lines in vitro. As shown in Fig. 2A, 
comparable rates of tumor cell proliferation was observed in 
plates regardless of their cell type and sensitivity. All of the 
tumor cells grew quickly in vitro and maintained proliferation 
activity.
The colony formation assay is an in vitro cell survival 
assay based on the ability of a single cell to grow into a colony, 
reflecting the possible malignant properties of tumor cells. 
Correlations between tumor cell colony formation and tumor 
growth in vivo have previously been reported (15,16). In our 
comparisons, both of drug sensitive KB-3-1 cells and the drug 
resistant H460/Tax-R cells preferred colony formation (Fig. 2), 
but these two types of cells presented completely different 
growth rate in the xenograft mouse (Fig. 1). Hitherto, there 
existed no correlation between colony formation and tumor 
growth in vivo.
In the mouse xenograft models we found the growth of drug 
resistant tumors (e.g., NCI/ADR-ReS and H460/Tax-R) to be 
slow (Fig. 1). In order to characterize the drug resistance we 
measured P-gp expression in different cell lines qualitatively 
using western blot analysis and nanoUPLC-MS/MS. As shown 
in Fig. 3, both methods showed the same trend of P-gp expres-
sion in the cell lines: NCI/ADR-ReS > H460/Tax-R > KB-8-5 
> KB-3-1. Slight P-gp expression was seen in KB-3-1 cells, 
which are sensitive to Taxol (17). More P-gp expression was 
observed in the other three resistant cell types (17). It followed 
that cells containing high P-gp levels (Fig. 3) showed low 
tumorigenesis in vivo (Fig. 1). It was therefore suggested that 
NIH/3T3 fibroblasts without P-gp expression (Fig. 3) would be 
tested as auxiliary cells for development of a resistant in vivo 
tumor model.
Analysis of tissue section of the low tumorigenesis tumor 
(H460/Tax-R). To further study the apparent negative correla-
tion between high P-gp levels and tumorigenesis, we assayed 
H460/Tax-R tumor tissue sections by immunofluorescence 
staining. Staining for α-SMA was performed because its 
expression is the major morphological characteristic of myofi-
broblasts which contribute greatly to tumor stroma and tumor 
growth in vivo (18). As shown in Fig. 4, abundant TAFs in the 
fast growing KB-8-5 tumor, and few TAFs in the H460/Tax-R 
tumor were observed, which had been a ‘tumor dot’ in the 
Figure 1. Tumor growth rate in nude mice administered subcutaneous inocu-
lation with one of the four types of cell line.
Figure 2. Tumor cell growth profiles in vitro. (A) Cell growth curves of var-
ious tumor cell lines. (B) Colony formation of drug sensitive cells (KB-3-1) 
and MDR cells (H460/Tax-R). MDR, multidrug resistance.
Figure 3. P-gp expression in various cells determined by western blot (A) and 
targeted quantitative proteomic analysis (B).
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mouse xenograft model (Fig. 1). The strong effect of TAFs 
on tumor growth has been widely reported (7,19). We believe 
that tumor cells in vivo containing high levels of P-gp have 
difficulty in recruiting TAFs, resulting in a lack of structural 
and chemical support necessary for tumor progression (20). 
We therefore decided to develop and test an MDR xenograft 
mouse model produced by co-inoculation with tumor cells and 
fibroblast cells.
Establishment and evaluation of a new mouse xenograft 
model. As expected, the MDR tumor model was successfully 
produced by co-inoculation with NIH/3T3 fibroblast (TAF) 
cells and H460/Tax-R or NCI/ADR-ReS cells (Fig. 5B and D). 
In our preliminary experiments, different ratios of tumor cells 
to NIH/3T3 cells (2:1 or 1:1) were tested but no obvious differ-
ences in tumor growth were observed. Moreover, the NIH/3T3 
cells did not form a tumor after being injected subcutaneously. 
All the results suggested that improvement of tumorigenesis is 
mainly due to modulation of the tumor by the fibroblasts and 
not growth of the fibroblasts themselves.
Tumor sensitivity to chemotherapy was investigated in the 
developed H460/Tax-R and NCI/ADR-ReS models. Taxol, a 
P-gp substrate, was chosen as the tumor resistant test agent and 
gemcitabine as the tumor sensitive agent (21-23). As shown in 
Fig. 5, Taxol exerted little effect on tumor growth for both cell 
types, indicating the successful establishment of the mouse 
Figure 4. Immunofluorescence staining for α-SMA expression in KB-8-5 (A) and H460/Tax-R (B). Nude mice were inoculated with KB-8-5 or H460/Tax-R 
cells subcutanously and sacrificed after 16 days. Tumor tissues were harvested and sectioned for immunofluorescence analysis following a common protocol. 
α-SMA, α-smooth muscle actin.
Figure 5. Sensitivity of the new mouse xenograft model to chemotherapy drugs. (A) H460/Tax-R tumor size progression as a function of time post-adminis-
tration. (B) Photographs of excised H460/Tax-R tumors after receiving different treatments. (C) NCI/ADR-ReS tumor size progression as a function of time 
post-administration. (D) Photographs of excised NCI/ADR-ReS tumors after receiving different treatments.
MA et al:  FIBRoBLAST-MoDULATeD MoUSe xeNogRAFT MoDeL FoR TUMoR MDR2704
xenograft model modulated by TAF cells. The observed anti-
cancer activity of gemcitabine ruled out the possibility that the 
poor response to Taxol was due to the change in microenviron-
ment of the tumors caused by the TAF cells. It is well known 
that the weak response to PTx is caused by the efflux of P-gp.
To further evaluate the applicability of the novel MDR 
tumor model, P-gp and α-SMA levels in tumor tissues were 
determined by western blot and immunofluorescence staining 
analysis. As shown in Fig. 6B, P-gp expression increased 
in the MDR tumor after Taxol treatment. This is consistent 
with previous studies that P-gp expression can be induced 
by Taxol (24). Higher P-gp levels in the Taxol-treated group 
confirm that the novel MDR model was successfully developed. 
In contrast, gemcitabine, to which MDR tumors are sensitive, 
did not increase P-gp expression in the model (Fig. 6B). The 
slightly higher level of α-SMA expression were observed in 
the tumors treated with Taxol compared to the control tumors. 
We supposed that the resistance of Taxol may be related to 
the increased TAF besides the efflux pump of P-gp. Further 
research is needed in our subsequent study.
overall, no antitumor effect was observed after Taxol 
treatment, mainly because the drug could not kill the MDR 
tumor cells or the fibroblasts, evident from an increase in P-gp 
levels and no obvious change in α-SMA expression when 
compared to the untreated group. In contrast, for gemcitabine, 
a significant decrease in tumor size and little change in α-SMA 
expression suggested that the gemcitabine acted mainly on the 
tumor cells. Therefore, without being affected by the added 
fibroblasts, the new human MDR mouse xenograft model 
should serve as a useful tool to evaluate the antitumor activity 
of drugs.
In conclusion, in the present study we investigated the 
common problems of developing a mouse xenograft model 
using tumor cell lines that highly express P-gp and exhibit low 
tumorigenesis in vivo.
Failure to recruit fibroblasts in vivo for tumor cells 
containing high levels of P-gp lies in less structural and chem-
ical support during tumor progression. A new mouse xenograft 
model applicable to MDR research has been successfully 
developed by co-inoculating with tumor cells (NCI/ADR-ReS 
Figure 6. P-gp and α-SMA expression in the new NCI/ADR-ReS tumor model determined by (A) immunofluorescence and (B and C) western blot analysis. 
The nuclei were stained with DAPi (blue) and α-SMA with Texas Red (red). α-SMA, α-smooth muscle actin.
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or H460/Tax-R) and fibroblast cells. The new MDR model is 
resistant to Taxol treatment, which affects neither the tumor 
cells nor the fibroblasts. In contrast, gemcitabine, to which 
MDR tumors are not resistant, inhibits tumor growth by killing 
tumor cells but exerts no obvious influence on fibroblasts. 
Fibroblasts in this tumor model therefore would not disturb 
application of the model in the research of MDR. The new 
mouse xenograft MDR model should serve as a useful tool to 
evaluate the antitumor effect of drugs.
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